{"nctId":"NCT03425539","briefTitle":"Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease","startDateStruct":{"date":"2018-06-21","type":"ACTUAL"},"conditions":["Fabry Disease"],"count":118,"armGroups":[{"label":"Lucerastat","type":"EXPERIMENTAL","interventionNames":["Drug: Lucerastat"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Lucerastat","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Signed and dated ICF prior to any study-mandated procedure;\n2. Male or female adult subjects;\n3. FD diagnosis confirmed with local genetic test results;\n4. Fabry-associated neuropathic pain, as defined by the subject, in the last 3 months prior to screening;\n5. Enzyme replacement therapy (ERT) status:\n\n   1. Subject never treated with ERT; or\n   2. Subject has not received ERT for at least 6 months prior to screening; or\n   3. Subject treated with ERT since at least 12 months at the time of the screening visit, and agreeing to stop ERT for approximately 8 months.\n6. A woman of childbearing potential is eligible only under certain conditions, e.g. taking contraceptive measures.\n7. Subjects with moderate or severe neuropathic pain during the screening period.\n\nExclusion Criteria:\n\n1. Pregnant, planning to be become pregnant, or lactating subject.\n2. Severe renal insufficiency (eGFR \\< 30 mL/min/1.73 m2) at screening.\n3. Subject on regular dialysis for the treatment of chronic kidney disease.\n4. Known and documented transient ischemic attack, stroke, unstable angina, or myocardial infarction within 6 months prior to screening.\n5. Clinically significant unstable cardiac disease (e.g. uncontrolled symptomatic arrhythmia, congestive heart failure NYHA class III or IV).\n6. Any known factor or disease that might interfere with treatment compliance, study conduct or interpretation of the results.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Neuropathic Pain Monthly Score: Change From Baseline to Month 6","description":"Neuropathic pain on the modified BPI-SF3: subjects rated their neuropathic pain intensity (\"neuropathic pain at its worst in the last 24 hours\") on an 11-point scale, from 0 (no neuropathic pain) to 10 (worst imaginable neuropathic pain).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.64","spread":null},{"groupId":"OG001","value":"-2.05","spread":null}]}]}]},{"type":"SECONDARY","title":"Plasma Globotriaosylceramide (Gb3; in ng/ml): Change From Baseline to Month 6","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-672.68","spread":null},{"groupId":"OG001","value":"200.84","spread":null}]}]}]},{"type":"SECONDARY","title":"Abdominal Pain Monthly Score: Change From Baseline to Month 6","description":"Abdominal pain on the 11-point Numerical Rating Scale (NRS-11): subjects rated their abdominal pain intensity (\"abdominal pain at its worst in the last 24 hours\") on an 11-point scale, from 0 (no pain) to 10 (worst imaginable pain).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.37","spread":null},{"groupId":"OG001","value":"-1.68","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Days With Diarrhea: Change From Baseline to Month 6","description":"A subject was considered to have diarrhea on a specific day if at least one stool of a Bristol Stool Scale (BSS) consistency Type 6 or 7 was reported. The number of days with diarrhea at baseline and Month 6 was the number of days with diarrhea over the 4 weeks prior to the randomization visit or the Month 6 visit, respectively, adjusted for the number of days with data available.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.45","spread":"4.96"},{"groupId":"OG001","value":"-3.95","spread":"9.29"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":80},"commonTop":["Nasopharyngitis","Headache","Nausea","Diarrhoea","Fatigue"]}}}